Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Legend Biotech's revenue for the
three
months ended in Mar. 2026 was $305 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $1,139 Mil.
Legend Biotech's Revenue per Share for the
three
months ended in Mar. 2026 was $1.65.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $6.17.
During the past 12 months, the average Revenue per Share Growth Rate of Legend Biotech was 55.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 96.50% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 64.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 8 years, Legend Biotech's highest 3-Year average Revenue per Share Growth Rate was 96.50% per year. The lowest was -0.10% per year. And the median was 36.60% per year.
Legend Biotech (NAS:LEGN) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Legend Biotech Revenue Related Terms
Legend Biotech Revenue Historical Data
* Premium members only.
The historical data trend for Legend Biotech's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Legend Biotech's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's Revenue distribution charts can be found below:
* The bar in red indicates where Legend Biotech's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,139 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a Revenue of $1,139 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Revenue too high?
Legend Biotech's current Revenue is $1,139 Mil. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Revenue compare to TVTX and ORKA?
Legend Biotech's Revenue of $1,139 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Legend Biotech and its competitors. Legend Biotech's current Revenue is $1,139 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $100.02, compared to a current price of $25.67 — trading 74.3% below its estimated fair value. The current Revenue is $1,139 Mil. Legend Biotech's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Revenue is $1,139 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $25.67 is trading 74.3% below its estimated GF Value™ of $100.02.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
Revenue: $1,139 Mil
GF Value™: $100.02 vs. price of $25.67 (74.3% below fair value)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score
Get the complete analysis for LEGN
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
